Skip to Content

New Drug Approvals Archive - July 2010

See also: New Indications and Dosage Forms for July 2010

July 2010

Zuplenz (ondansetron) Oral Soluble Film

Date of Approval: July 2, 2010
Company: Strativa Pharmaceuticals
Treatment for: Prevention of Chemotherapy-Induced, Radiotherapy-Induced, and Postoperative Nausea and Vomiting

Zuplenz is an oral soluble film formulation of ondansetron for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

Glassia (alpha1-proteinase inhibitor (human)) Injection - formerly AAT-IV

Date of Approval: July 1, 2010
Company: Kamada Ltd.
Treatment for: Alpha-1 Proteinase Inhibitor Deficiency

Glassia is an alpha1-proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1antitrypsin deficiency.

Veltin (clindamycin and tretinoin) Gel - formerly Velac

Date of Approval: July 16, 2010
Company: Stiefel Laboratories, Inc.
Treatment for: Acne

Veltin Gel (clindamycin phosphate and tretinoin) is a combination of an antibiotic and a retinoid indicated for the topical treatment of acne vulgaris.

Tribenzor (amlodipine, hydrochlorothiazide and olmesartan) Tablets

Date of Approval: July 23, 2010
Company: Daiichi Sankyo, Inc.
Treatment for: Hypertension

Tribenzor (amlodipine, hydrochlorothiazide and olmesartan) is a three-in-one combination product taken once-daily for the treatment of hypertension.

Lastacaft (alcaftadine) Ophthalmic Solution

Date of Approval: July 28, 2010
Company: Allergan, Inc.
Treatment for: Allergic Conjunctivitis

Lastacaft (alcaftadine ophthalmic solution) is a topical H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.

Cuvposa (glycopyrrolate) Oral Solution

Date of Approval: July 28, 2010
Company: Shionogi Pharma Inc.
Treatment for: Chronic Drooling in Children

Cuvposa (glycopyrrolate) oral solution is an anticholinergic for the treatment of chronic severe drooling caused by neurologic disorders in children.

Xeomin (incobotulinumtoxinA) Injection

Date of Approval: July 30, 2010
Company: Merz Pharmaceuticals, LLC
Treatment for: Cervical Dystonia, Blepharospasm, Glabellar Lines, Upper Limb Spasticity, Excessive Salivation

Xeomin (incobotulinumtoxinA) is a botulinum toxin type A for the treatment of cervical dystonia, blepharospasm, glabellar lines, upper limb spasticity, and excessive drooling.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.